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Introduction
Shigella are a group of pathogenic bacteria under the Enterobacteriaceae family. They
are gram-negative, non-motile, facultatively anaerobic bacteria which include four main
subgroups: Shigella flexneri, Shigella boydii, Shigella sonnei, and Shigella dysenteriae. Of the
four subgroups, S. dysenteriae is associated with the most severe outbreaks due to its high
infection-fatality rate in low-income areas of central Asia, central America, and southeastern
Africa. S. flexneri and S. sonnei are considered to be the most ubiquitous subgroups, and
collectively, they are responsible for the majority of Shigella cases globally. S. boydii is the least
common subgroup, most likely due to its specificity to the India sub-region. When considering
the United States and other high-income countries, S. sonnei is considered to be the most
infectious subgroup (Kotloff et al, 2018; Baker and The, 2018). Figure 1 shows that from 19902014, the United States had a >3:1 ratio of S. sonnei to S. flexneri isolates.

Fig. 1: The ratio of S. sonnei to S. flexneri infections isolated from 100 countries, 1990-2014. The
darker the color, the more often S. sonnei was isolated compared to S. flexneri. The lighter the
color, the more proportionally S. flexneri was isolated. Grey areas indicate countries where no
data was collected (Thompson et al, 2015).

Victims of Shigella infection often contract a form of shigellosis, a disease which
primarily induces aggressive dysentery. Other symptoms associated with shigellosis include
fever, abdominal cramping, vomiting, dehydration, and nutrient deficiency. In rare cases,
shigellosis from S. flexneri can additionally cause Reiter’s syndrome (reactive arthritis) postinfection. Shigella are predominantly transferred via fecal-oral contamination, but the bacteria
can also be foodborne or waterborne. Recent studies have also concluded that Shigella can be
transferred via houseflies (Kotloff et al, 2018). In the United States alone, Shigella infections
cause approximately half a million infections, 6,000 hospitalizations, and 70 deaths annually
(Kozryeva et al, 2016). This manuscript will compare Shigella to pathogenic Escherichia coli and
explain how Shigella developed their own virulence mechanisms. Then, groups that are of
particular risk to Shigella infection will be discussed, followed by an analysis of the increasing
antibiotic resistance in Shigella found in the United States, and what those increases imply for
the future.
Genotypic comparison of Shigella to E. coli
Current genomic research indicates that Shigella species originated from pathogenic
strains of Escherichia coli. Both Shigella and pathogenic E. coli contain the virulence plasmid
pINV, which contains coding for a unique virulence mechanism called the type 3 secretion
system (T3SS). T3SS allows bacteria to inject effector proteins directly into the cytosol of host
cells to illicit an array of responses (Kotloff et al, 2018). The pINV plasmid also holds sequences
for a number of Shiga toxins shared between Shigella and E.coli. Despite these fundamental
similarities to E. coli, however, Shigella subgroups have a number of evolutionary divergences
that are unique. Primarily, Shigella bacteria have developed traits such as proton consumption
systems, producing mucinases, and host antimicrobial resistance (Kotloff et al, 2018). All of
these play an important role in Shigella survivability. Shigella also diverged from E. coli by losing
motility, and several metabolic pathways common to E. coli are no longer present in Shigella.
Most of these metabolic pathways are still not fully understood. Table 1 compares key
relationships between Shigella and pathogenic E. coli.

Trait

Shigella

Pathogenic E. coli

Lactose fermentation

-*

+

Salicin fermentation

-

+

Motility

-

+

pINV plasmid

+

+

Can cause Haemolytic

+

+

+

+

Uraemic Syndrome
Presence of Shiga toxins
*Only in the case of S. sonnei
Table 1: Comparison of trait presence/absence between Shigella and pathogenic E. coli. “-”
denotes the absence of a trait, whereas “+” represents the presence of a trait. Table
synthesized using information from another manuscript (Ud-Din and Wahid, 2014).
Much of Shigella genome divergence can be related to the high ratio of insertion
sequences (IS) to gene counts within Shigella chromosomes (Fig. 2). These IS are transposable
elements able to move genetic material on chromosomes, thus causing mutations. Studies have
proven that Shigella chromosomes can contain approximately 13-42 times more IS than those
of pathogenic E. coli (Hawkey et al, 2019). This means that Shigella bacteria are likely to mutate
more often than other similar bacteria, thus increasing the chance for genome divergence.

Figure 2: Box plots of five IS genes common to shown Shigella species and E. coli species
(Hawkey et al, 2019).
Pathogenicity of Shigella
Research has connected Shigella pathogenicity to high in-host survivability and low
infectious dose. Infections can be contracted after ingestion of less than 10-200 organisms, and
symptoms usually show within 12-50 hours. Once within the human body, Shigella can survive
stomach acid and the numerous competitive intestinal microbiota, ultimately settling on the
mucosal layers of the ileum, colon, and rectum. The bacterial cells are phagocytized by
Microfold cells (M-cells), allowing Shigella to inject effector proteins into the M-cells using T3SS
(Kotloff et al, 2018).
Although the exact mechanism is not fully understood, research indicates that the
injection of effectors like the invasion plasmid antigen H (IpaH) family proteins ultimately
induces the reorientation of actin polymerization, allowing Shigella to provoke intracellular
motility. Therefore, the bacterial cells are able to hijack host cells to move and replicate in
neighboring epithelial cells, consequently stirring inflammatory cell death and severe intestinal
inflammation (Ashida and Sasakawa, 2016).
Groups at risk
Although Shigella poses a threat to everyone, there are some groups that are notably
more susceptible than others. Transmission in these areas is mostly a result of underdeveloped
food/water quality and under-privileged sanitation/hygiene. Therefore, it is not surprising that
the majority of shigellosis cases arise from young children (ages 1-4) in low to middle-income
countries. In the United States, the age trend is similar. Most shigellosis cases stem from
children held in day-care facilities (Kotloff et al, 2018). However, a recent S. sonnei outbreak
within a retirement community in Vermont revealed that elderly and immunocompromised
individuals are also likely to be more susceptible (Strysko et al, 2019). People traveling from
high-income to low/middle-income countries are another group that is more vulnerable to
Shigella infection. Studies have shown that Shigella is one of the leading causes of diarrheal
infection for these groups (Khalil et al, 2018). It is also worth mentioning that over the past few

years, men who have sex with other men (MSM) have shown an increasing number of Shigella
infections. Several case studies have identified instances where Shigella have been passed
sexually between MSM (Kennedy et al, 2017; Bowen et al, 2016; Heiman et al, 2014). The
spread of Shigella infection via travel and MSM are also proven to be large contributors to the
growing antibiotic resistance in Shigella, particularly S. sonnei.
Antibiotic resistance in Shigella
The use of antibiotics has been the primary solution for Shigella infections for many
years, but as a result, drug resistance is an ever-increasing issue. Studies on antibiotic resistance
in Shigella all show trends of increasing resistance to commonly used antibiotic treatments. In
the mid-late 1900s, streptomycin, tetracycline, and trimethoprim-sulfamethoxazole were some
of the most prescribed antibiotics in the United states to reduce symptoms and pathogen
shedding from Shigella species. However, by the 21st century, the majority of Shigella isolates
showed resistance to all these (Howie et al, 2010). Afterward, ampicillin and co-trimoxazole
became the primary antibiotics used to treat Shigella cases. Similarly, Shigella quickly
developed resistance to these drugs. Nalidixic acid and fluoroquinolones were introduced to
replace previous treatments, but Shigella species acquired resistance to these antibiotics as
well (Puzari et al, 2018). In 2006, a study tested 1,604 Shigella isolates for antibiotic resistance
and concluded that all of them were susceptible to ceftriaxone (Sivapalasingam et al, 2006).
More recently however, studies have found Shigella isolates with resistance to ceftriaxone
(Puzari et al, 2018).
As of now, ciprofloxacin is recommended as the primary antibiotic used to treat Shigella
in adults and children. Unfortunately, studies have shown an increasing resistance to this
antibiotic as well (Fig. 3). In 2017, the CDC issued a health advisory urging that the use of
antibiotics for Shigellosis be reserved for only the most serious cases due to the noticeable
increase in ciprofloxacin resistance. As Shigella continue to develop resistance to our best
treatment methods, it is imperative that the mechanisms and origins of resistance in Shigella be
further identified and understood.
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Figure 3: Data was collected and synthesized from the National Antimicrobial Resistance
Monitoring System (NARMS)
As mentioned previously, much of the growing antibiotic resistance in Shigella
correllates with the high amount of IS present on Shigella chromosomes, the transmission of
bacterial strains from travel, and the transmission via MSM. Antibiotic resistance in Shigella and
other pathogenic bacteria resides within specific genes. An antibiotic resistance gene codes for
mechanisms that ultimately give resistance against a specific antibiotic, and these genes are
able to be passed between different strains of Shigella. As people travel between high to
low/middle-income countries, antibiotic resistance genes are able to be passed amongst
Shigella and spread around the world. Table 1 lists antibiotic resistance in S. sonnei isolates
collected from the United States and how resistance relates with travel (Abelman et al, 2019).
Studies also have concluded that MSM can not only transfer Shigella to one another sexually,
but MSM also may be more susceptible to multi-drug resistant strains of Shigella. It is known
that HIV-positive men have a higher potential for co-infections with Shigella as well as
increased potential for relapsed infection.

This raised risk of infection combined with sexual interaction increases the transmission of
antibiotic resistance genes among strains of S. sonnei and S. flexneri (Baker et al, 2015).
PSU-ID
SS-27
SS-2
SS-28
SS-29
SS-32
SS-36
SS-39
SS-40
SS-3
SS-4
SS-5
SS-43
SS-38
SS-42
SS-37
SS-26
SS-30
SS-31
SS-21
SS-24
SS-35
SS-23

Travel history
None
None
None
None
None
None
None
None
None
None
None
Mexico
Dominican
Republic
Dominican
Republic
Haiti
Jamaica
Peru
Peru
India
India
India
Nepal

Year of isolation
2010
2011
2011
2011
2012
2012
2013
2013
2013
2013
2014
2014
2013

AMR profile
STR, AMP, SXT, SMX, TET
STR, AMP, AMC, FOX, TET
STR, AMP, AMC, FOX
STR, AMP, AMX, FOX
AMP, AMC, SXT, CHL, SMX, TET
STR, SXT, CIP, NAL, SMX, TET
STR, SXT, CIP, NAL, SMX, TET
STR, AMP, SXT, SMX, TET
GEN, STR, SXT, SMX, TET, AZM
STR, SXT, SMX, TET
STR, AMP, SXT, SMX, TET, AZM
STR, SXT, NAL, SMX, TET
STR, AMP, SXT, SMX, TET

2014

STR, SXT, NAL, SMX, TET

2013
2010
2012
2012
2009
2010
2012
2009

STR, AMP, SXT, SMX, TET
STR, SXT, NAL, SMX, TET
AMP, AMC, SXT, CHL, SMX, TET
AMP, AMC, SXT, CHL, SMX, TET
STR, SXT, NAL, SMX, TET
STR, SXT, CIP, NAL, SMX, TET
STR, SXT, CIP, NAL, SMX, TET
STR, SXT, CIP, NAL, SMX, TET

Table 2: All isolates were taken from the Pennsylvania Department of Health. Travel History
highlights where the Shigella isolate originated from. “None” values in this column imply that
the person from which this isolate was collected from did not report any travel outside of the
U.S. Isolates that showed resistance to ciprofloxacin or azithromycin are highlighted.
Antimicrobial Resistance (AMR) abbreviations represent as follows: streptomycin (STR),
gentamicin (GEN), ampicillin (AMP), amoxicillin (AMC), cefoxitin (FOX), trimethoprimsulfamethoxazole (SXT), sulfamethoxazole (SMX), tetracycline (TET), chloramphenicol (CHL),

ciproflaxin (CIP), nalidixic acid (NAL), and azithromycin (AZM). Table modified from (Abelman et
al, 2019).
Conclusion
Shigella is a widespread, highly pathogenic bacteria that causes many infections and
deaths worldwide. In the United States and other high-income countries, S. sonnei is the most
concerning subgroup, due to its high drug resistance. Over several years, studies have indicated
that Shigella is highly adaptable. Shigella continues to quickly develop antibiotic resistance to
commonly used antibiotics in the United States. Some of the bacteria’s fast response to new
antibiotics can be connected back to the high amounts of IS sequences present within Shigella
chromosomes. These sequences allow the bacteria to undergo rapid mutations to develop
antibiotic resistant genes. As multi-drug resistance continues to gain more attention,
researchers are beginning to develop new solutions to reduce the need for so many antibiotics.
Using genome sequencing, scientists are now able to observe the entire genome of a particular
strain of Shigella to identify the antibiotic resistance genes present. Identification of these
genomes will allow for more specific treatment of Shigella infections, ultimately increasing the
number of successful treatments while also slowing the rate of antibiotic resistance
development. However, the exact mechanism of these antibiotic resistance genes needs to be
better understood before this form of treatment could be viable. These sequences contain
unique, often complex mechanisms for a particular resistance gene, and it will take time to fully
understand them at a level which treatment could be effectively prescribed. Additionally, new
mechanisms will inevitably continue to develop in Shigella species, so researching these
mechanisms would essentially be a never-ceasing process. Another treatment option highlights
taking preventative measures via vaccination. Tests have already indicated that Opolysaccharide conjugate vaccines reduce the severity of Shigella infections (Kotloff et al,
2018). However, it is important to note that these vaccinations were serotype specific. Until a
vaccine providing cross-species immunity is established, it will be difficult for vaccination to
keep up with the rate of change in strains of S. sonnei and S. flexneri. Until further treatment
methods can be bolstered, it is important to moderate Shigella infections by practicing good
hygiene.
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